Last checked at 21 Feb 2019 07:00
21 February 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Change of Auditor
Scancell Holdings Plc (AIM: SCLP) announces that following the conclusion of a formal tendering process overseen by the Company's Audit Committee, the Scancell Board is pleased to appoint BDO LLP ("BDO") as the Company's independent auditor for the financial year ending 30 April 2019, effective immediately. The appointment of BDO for the financial year ending 30 April 2020 will be subject to approval by the Company's shareholders at the next Annual General Meeting to be held in 2019.
Champion Accountants LLP ("Champion"), who did not participate in the tender, has confirmed that there are no circumstances connected with its resignation which it considers should be brought to the attention of members or creditors of the Company.
The Board of Scancell would like to thank Champion for its service over the years.
For Further Information:
Scancell Holdings Plc | ||
Dr John Chiplin, Chairman | +44 (0) 20 3727 1000 | |
Dr Cliff Holloway, CEO | ||
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) | ||
Freddy Crossley/Emma Earl | +44 (0) 20 7886 2500 | |
FTI Consulting Simon Conway/Natalie Garland-Collins | +44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk
Further details about BDO can be found at their website: www.bdo.co.uk